1. Pink Sheet
  2. >>R&D
  3. >>Clinical Trials

Can Checkpoint Inhibitors Jump-Start Glioblastoma Drug Development?

 
• By Emily Hayes

The recent failure of Celldex’s vaccine Rintega was disappointing, but that has not dampened researchers’ enthusiasm for immunotherapy in the high-risk, high-reward glioblastoma field.

It’s early days yet, but checkpoint immunotherapies have the potential to jump-start the high-risk, high reward glioblastoma drug development space, which has been prone to many a setback, the latest casualty being Celldex Therapeutics Inc.’s Rintega vaccine.

Checkpoint inhibitors, namely Bristol-Myers Squibb Co.’s Yervoy and Opdivo, Merck & Co. Inc.’s Keytruda and Roche’s newly...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

EU Countries Rally Behind Novel Pathway For Combined Drug/IVD Trials

 
• By Vibha Sharma

Broad participation by EU member states in a new pilot to test a unified procedure for evaluating applications for combined drug and IVD studies shows they recognize its value, says Monique Al, vice-chair of the Clinical Trials Coordination Group.

UK Pilots Faster Setup Of Early Phase Oncology Trials

 
• By Vibha Sharma

Oncology trial sponsors in the UK are being invited to participate in a pilot that aims to tackle duplication and variation in pharmacy reviews, which are an important part of setting up clinical trials in the National Health Service.

CAR-T Therapy Trials Involving Chinese Labs Will Face Heightened US FDA Scrutiny

 
• By Michael McCaughan

The FDA wants to ensure participants in clinical trials involving genetic engineering done in China understand what the agency sees as privacy and security risks. The agency also wants cell therapy processing done outside of “hostile” countries.

EU Sees Unified Pathway For Drug/IVD Studies As Key To Future Research Investment

 
• By Vibha Sharma

As the EU tests the feasibility of a radical “all-in-one” procedure for reviewing applications to conduct combined drug and IVD studies, sponsors are being urged to approach this novel framework with flexibility and openness.

More from R&D

EU Sees Unified Pathway For Drug/IVD Studies As Key To Future Research Investment

 
• By Vibha Sharma

As the EU tests the feasibility of a radical “all-in-one” procedure for reviewing applications to conduct combined drug and IVD studies, sponsors are being urged to approach this novel framework with flexibility and openness.

New Drug Procurement Rules Aim To Drive Pharma Investment In Mexico

 
• By Francesca Bruce

Legal experts warn, however, that new Mexican procurement rules are discriminatory and could be challenged in the courts.

EMA Explores Supporting Drug Development For High Unmet Need Disorder Scleroderma

 
• By Neena Brizmohun

While treatments for scleroderma are in development, none are approved for the condition that is associated with high morbidity and mortality. The European Medicines Agency says guidance on how to design development programs for the disorder is needed.